FXR functional abnormalities have been associated with the development of NAFLD; thus, targeting FXR could be a therapeutic strategy to control NAFLD (Fiorucci et al., 2020). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.